Lalsoacidipine modulates the secretion of matrix metalloproteinase-9 by human macrophages

Stefano Bellosta, Monica Canavesi, Elda Favari, Luciano Cominacini, Giovanni Gaviraghi, Remo Fumagalli, Rodolfo Paoletti, Franco Bernini

Research output: Contribution to journalArticle

Abstract

Activated macrophages within the arterial wall secrete matrix-degrading metalloproteinases (MMPs) that weaken the atherosclerotic plaque and contribute to its fissuration. Preclinical studies have shown that calcium antagonists may reduce atherogenesis in the arterial wall. In the present study we evaluated the effect of lacidipine on 92-kDa gelatinase B (MMP-9) expression in human macrophages in cultures. Cells were treated for 24 h with lacidipine and the conditioned media were analyzed. Lacidipine (1-20 μM) significantly reduced, in a dose-dependent manner, MMP-9 potential gelatinolytic capacity up to 50%. When MMP-9 expression was stimulated by treatment with phorbol esters or tumor necrosis factor-α, lacidipine was able to inhibit this enhanced gelatinolytic capacity up to 50 and 60%, respectively. Western blot analysis and enzyme-linked immunosorbent assay showed a reduction of MMP-9 protein actually released by cells. The addition of lacidipine in the incubation media determined no significant variation in Ca2+ concentration. The drug did not affect MMP-9 mRNA levels, but it effectively reduced the amount of both active and total free MMP-9 secreted by human macrophages. Lacidipine reduced also the secretion of the tissue inhibitor of metalloproteinase-1 (TIMP-1); however we observed an overall reduction of the gelatinolytic activity of the cells. Finally, peritoneal macrophages, obtained from mice treated with lacidipine, showed a reduced secretion of MMP-9. Together, our data indicate that lacidipine may potentially exert an antiatherosclerotic activity by modulating the secretion of MMP-9 by macrophages. This, in addition to the previously demonstrated inhibition of cholesterol esterification, may contribute to increase plaque stability.

Original languageEnglish
Pages (from-to)736-743
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume296
Issue number3
Publication statusPublished - 2001

Fingerprint

Matrix Metalloproteinase 9
Macrophages
human MMP9 protein
Tissue Inhibitor of Metalloproteinase-1
lacidipine
Esterification
Peritoneal Macrophages
Phorbol Esters
Atherosclerotic Plaques
Conditioned Culture Medium
Matrix Metalloproteinases
Atherosclerosis
Tumor Necrosis Factor-alpha
Western Blotting
Enzyme-Linked Immunosorbent Assay
Cholesterol
Calcium
Messenger RNA

ASJC Scopus subject areas

  • Pharmacology

Cite this

Bellosta, S., Canavesi, M., Favari, E., Cominacini, L., Gaviraghi, G., Fumagalli, R., ... Bernini, F. (2001). Lalsoacidipine modulates the secretion of matrix metalloproteinase-9 by human macrophages. Journal of Pharmacology and Experimental Therapeutics, 296(3), 736-743.

Lalsoacidipine modulates the secretion of matrix metalloproteinase-9 by human macrophages. / Bellosta, Stefano; Canavesi, Monica; Favari, Elda; Cominacini, Luciano; Gaviraghi, Giovanni; Fumagalli, Remo; Paoletti, Rodolfo; Bernini, Franco.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 296, No. 3, 2001, p. 736-743.

Research output: Contribution to journalArticle

Bellosta, S, Canavesi, M, Favari, E, Cominacini, L, Gaviraghi, G, Fumagalli, R, Paoletti, R & Bernini, F 2001, 'Lalsoacidipine modulates the secretion of matrix metalloproteinase-9 by human macrophages', Journal of Pharmacology and Experimental Therapeutics, vol. 296, no. 3, pp. 736-743.
Bellosta S, Canavesi M, Favari E, Cominacini L, Gaviraghi G, Fumagalli R et al. Lalsoacidipine modulates the secretion of matrix metalloproteinase-9 by human macrophages. Journal of Pharmacology and Experimental Therapeutics. 2001;296(3):736-743.
Bellosta, Stefano ; Canavesi, Monica ; Favari, Elda ; Cominacini, Luciano ; Gaviraghi, Giovanni ; Fumagalli, Remo ; Paoletti, Rodolfo ; Bernini, Franco. / Lalsoacidipine modulates the secretion of matrix metalloproteinase-9 by human macrophages. In: Journal of Pharmacology and Experimental Therapeutics. 2001 ; Vol. 296, No. 3. pp. 736-743.
@article{1f65cb3aca82468ca470ca501ad3a6d9,
title = "Lalsoacidipine modulates the secretion of matrix metalloproteinase-9 by human macrophages",
abstract = "Activated macrophages within the arterial wall secrete matrix-degrading metalloproteinases (MMPs) that weaken the atherosclerotic plaque and contribute to its fissuration. Preclinical studies have shown that calcium antagonists may reduce atherogenesis in the arterial wall. In the present study we evaluated the effect of lacidipine on 92-kDa gelatinase B (MMP-9) expression in human macrophages in cultures. Cells were treated for 24 h with lacidipine and the conditioned media were analyzed. Lacidipine (1-20 μM) significantly reduced, in a dose-dependent manner, MMP-9 potential gelatinolytic capacity up to 50{\%}. When MMP-9 expression was stimulated by treatment with phorbol esters or tumor necrosis factor-α, lacidipine was able to inhibit this enhanced gelatinolytic capacity up to 50 and 60{\%}, respectively. Western blot analysis and enzyme-linked immunosorbent assay showed a reduction of MMP-9 protein actually released by cells. The addition of lacidipine in the incubation media determined no significant variation in Ca2+ concentration. The drug did not affect MMP-9 mRNA levels, but it effectively reduced the amount of both active and total free MMP-9 secreted by human macrophages. Lacidipine reduced also the secretion of the tissue inhibitor of metalloproteinase-1 (TIMP-1); however we observed an overall reduction of the gelatinolytic activity of the cells. Finally, peritoneal macrophages, obtained from mice treated with lacidipine, showed a reduced secretion of MMP-9. Together, our data indicate that lacidipine may potentially exert an antiatherosclerotic activity by modulating the secretion of MMP-9 by macrophages. This, in addition to the previously demonstrated inhibition of cholesterol esterification, may contribute to increase plaque stability.",
author = "Stefano Bellosta and Monica Canavesi and Elda Favari and Luciano Cominacini and Giovanni Gaviraghi and Remo Fumagalli and Rodolfo Paoletti and Franco Bernini",
year = "2001",
language = "English",
volume = "296",
pages = "736--743",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Lalsoacidipine modulates the secretion of matrix metalloproteinase-9 by human macrophages

AU - Bellosta, Stefano

AU - Canavesi, Monica

AU - Favari, Elda

AU - Cominacini, Luciano

AU - Gaviraghi, Giovanni

AU - Fumagalli, Remo

AU - Paoletti, Rodolfo

AU - Bernini, Franco

PY - 2001

Y1 - 2001

N2 - Activated macrophages within the arterial wall secrete matrix-degrading metalloproteinases (MMPs) that weaken the atherosclerotic plaque and contribute to its fissuration. Preclinical studies have shown that calcium antagonists may reduce atherogenesis in the arterial wall. In the present study we evaluated the effect of lacidipine on 92-kDa gelatinase B (MMP-9) expression in human macrophages in cultures. Cells were treated for 24 h with lacidipine and the conditioned media were analyzed. Lacidipine (1-20 μM) significantly reduced, in a dose-dependent manner, MMP-9 potential gelatinolytic capacity up to 50%. When MMP-9 expression was stimulated by treatment with phorbol esters or tumor necrosis factor-α, lacidipine was able to inhibit this enhanced gelatinolytic capacity up to 50 and 60%, respectively. Western blot analysis and enzyme-linked immunosorbent assay showed a reduction of MMP-9 protein actually released by cells. The addition of lacidipine in the incubation media determined no significant variation in Ca2+ concentration. The drug did not affect MMP-9 mRNA levels, but it effectively reduced the amount of both active and total free MMP-9 secreted by human macrophages. Lacidipine reduced also the secretion of the tissue inhibitor of metalloproteinase-1 (TIMP-1); however we observed an overall reduction of the gelatinolytic activity of the cells. Finally, peritoneal macrophages, obtained from mice treated with lacidipine, showed a reduced secretion of MMP-9. Together, our data indicate that lacidipine may potentially exert an antiatherosclerotic activity by modulating the secretion of MMP-9 by macrophages. This, in addition to the previously demonstrated inhibition of cholesterol esterification, may contribute to increase plaque stability.

AB - Activated macrophages within the arterial wall secrete matrix-degrading metalloproteinases (MMPs) that weaken the atherosclerotic plaque and contribute to its fissuration. Preclinical studies have shown that calcium antagonists may reduce atherogenesis in the arterial wall. In the present study we evaluated the effect of lacidipine on 92-kDa gelatinase B (MMP-9) expression in human macrophages in cultures. Cells were treated for 24 h with lacidipine and the conditioned media were analyzed. Lacidipine (1-20 μM) significantly reduced, in a dose-dependent manner, MMP-9 potential gelatinolytic capacity up to 50%. When MMP-9 expression was stimulated by treatment with phorbol esters or tumor necrosis factor-α, lacidipine was able to inhibit this enhanced gelatinolytic capacity up to 50 and 60%, respectively. Western blot analysis and enzyme-linked immunosorbent assay showed a reduction of MMP-9 protein actually released by cells. The addition of lacidipine in the incubation media determined no significant variation in Ca2+ concentration. The drug did not affect MMP-9 mRNA levels, but it effectively reduced the amount of both active and total free MMP-9 secreted by human macrophages. Lacidipine reduced also the secretion of the tissue inhibitor of metalloproteinase-1 (TIMP-1); however we observed an overall reduction of the gelatinolytic activity of the cells. Finally, peritoneal macrophages, obtained from mice treated with lacidipine, showed a reduced secretion of MMP-9. Together, our data indicate that lacidipine may potentially exert an antiatherosclerotic activity by modulating the secretion of MMP-9 by macrophages. This, in addition to the previously demonstrated inhibition of cholesterol esterification, may contribute to increase plaque stability.

UR - http://www.scopus.com/inward/record.url?scp=0035122809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035122809&partnerID=8YFLogxK

M3 - Article

C2 - 11181900

AN - SCOPUS:0035122809

VL - 296

SP - 736

EP - 743

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -